Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Impact · against what's priced in

Vanda Pharmaceuticals faces a valuation haircut following the failure of its late-stage anxiety drug candidate. The decision to put the program on hold eliminates a key growth lever for the company's long-term revenue pipeline.

VNDA−0.80: No priced-in read yet
In context: The failure of a late-stage anxiety drug to meet its primary endpoint and the subsequent suspension of the program remove a potential future revenue stream.
Read from the article alone

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

biotech▲3%
healthcare
pharmaceuticals
VNDA
clinical trial
drug failure

Top 1 mover · tap to explore

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

What matters in this story

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

What matters in this story

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

How each ticker is affected

Track these names every morning.

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

Roche Expands Obesity Pipeline With Rona's RNAi Candidate

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

What matters in this story

Next reads from the same story arc

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

What matters in this story

Next reads from the same story arc

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

How each ticker is affected

Track these names every morning.

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

Roche Expands Obesity Pipeline With Rona's RNAi Candidate

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit